オンコスタチンM誘発のABCC2抑制は,肝細胞癌細胞を化学療法薬に敏感にする
Maciej Przywarty1, Błażej Rychlik1, Anna Wieczorek-Błauż2
1Centre for Digital Biology and Biomedical Science - Biobank Lodz, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, Łódź 90-236, Poland.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|February 22, 2026
まとめ
オンコスタチンM (OSM) は,肝臓がん細胞におけるABCC2トランスポーターの発現を減少させます. この発見は,OSMが薬剤耐性における重要な要因である胆管輸送に影響を及ぼすことを示唆しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 細胞生物学 細胞生物学
- 薬理学 薬理学とは
背景:
- オンコスタチンM (OSM) は,インターリューキン-6ファミリーのサイトカインで,腫瘍細胞の増殖を抑制し,血液形成過程を調節することが知られている.
- また,OSMは,多剤耐性 (MDR) で重要なサイトクロームP-450およびATP結合カセット (ABC) 超家族タンパク質に影響を与えます.
研究 の 目的:
- ABCC2トランスポーター (cMOAT) の発現と活動にOSMの役割と影響を調査する.
- この研究のモデルとして,肝細胞癌 (Hep G2) 細胞系を利用します.
主な方法:
- 肝細胞癌 (Hep G2) 細胞系がモデルシステムとして使用されました.
- この研究は,OSMの影響下でABCC2トランスポーターの発現と活動レベルを評価することに焦点を当てました.
主要な成果:
- オンコスタチンM (OSM) は,Hep G2細胞におけるABCC2トランスポーターの発現を減少させることが判明しました.
- 観察されたABCC2発現の減少は,胆管輸送に潜在的な影響を及ぼします.
結論:
- OSMはABCC2の発現を調節し,ABCC2は細胞流出に関与する重要なトランスポーターである.
- この発見は,OSMが胆管輸送機構の変化における潜在的な役割を果たす可能性を示唆し,薬物処分とMDRに影響を及ぼします.
キーワード:
ABCC2ABCC2 ABCC2ABCC2 ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2ABCC2C2C2C2C2C2C2C2C2C2C2C2C2C2C2C2C2C2C2MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR,MDR多剤耐性多剤耐性は,多剤耐性多剤耐性多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が,多剤耐性が.オンコスタチンM (オンコスタチンM)さらに関連する動画
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.9K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
4.0K
関連する概念動画
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:46Electron Transport Chain: Complex I and II
19.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.2K